About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNPhase 2NCT05701384

Lazertinib 160mg in EGFR T790M NSCLC

The lazertinib is currently approved as 2nd line T790M mutation-positive NSCLC that failed from either 1st or 2nd generation EGFR TKI. The current recommended dosage is 240mg. Based on the promising c...

Lead sponsor: Samsung Medical Center•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Samsung Medical Center

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Pathologically confirmed non-small cell lung cancer
•Patients in a palliative setting who is not applicable for the curative treatment
•EGFR mutation positive patients who received previous 1st or 2nd generation EGFR TKI
•Confirmed EGFR T790M mutation after the previous EGFR TKI
•Available to receive lazertinib either as po or vis levine tube
•Willing to participate clinical trial
•Age over or equal to 19
•ECOG PS 0 to 2

Exclusion Criteria

•Previously received 3rd generation EGFR TKI
•No clinical benefit is expected based on the investigator's decision
•Uncontrolled symptomatic CNS metastases
•Uncontrolled systemic disease

Related studies

RECRUITINGPhase 2

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

NCT07250477 · Non-small Cell Lung Cancer Stage IIIC, Non-small Cell Lung Cancer Stage IV, and more

RECRUITINGEARLY Phase 1

[177Lu]Lu-AKIR001 First-in-human Study

NCT06639191 · Thyroid Gland Anaplastic Carcinoma, Poorly Differentiated Thyroid Carcinoma, and more

Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation

NCT06573073 · Non Small Cell Lung Cancer, EGFR T790M

Not Yet RecruitingPhase 2

Screening for Brain Metastases

NCT07492121 · Lung Cancer Stage IV, Melanoma Stage IV, and more

TERMINATEDPhase 1/2

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

NCT05860296 · Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 27, 2023Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE2

Enrollment117

Start dateFeb 2023

Last updatedJan 27, 2023

Condition

Lung Cancer Stage IV EGFR T790M

Locations shown

Samsung Medical Center

Seoul, MA

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 27, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions